oritavancin (orbactiv) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oritavancin is an glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. It treats complicated skin and skin structure infections. This drug demonstrates similar activity to vancomycin, but it has stronger activity against Staphylococcus and Enterococcus. The pharmacokinetics and pharmacodynamics of oritavancin appear to be favourable and once-daily dosing is likely. The incidence of multi-drug resistant bacteria is increasing and explorations into additional treatment options are essential. Oritavancin is marketed under the brand name Orbactiv. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. Oritavancin has the following mechanism of action: 1) Inhibition of the transglycosylation (polymerisation) step of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors 2) Inhibition of the transpeptidation (crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall 3) Disruption of bacterial membrane integrity, leading to depolarisation, increased permeability and rapid cell death.   NCATS

Chemistry

  • SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O[C@H]3C[C@](C)(N)[C@@H](O)[C@H](C)O3)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(NCc3ccc(-c4ccc(Cl)cc4)cc3)[C@@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O.O=P(O)(O)O.O=P(O)(O)O
  • InChIKey: PWTROOMOPLCZHB-BHYQHFGMSA-N
  • Mol. Mass: 1989.11
  • ALogP: Missing data
  • ChEMBL Molecules:
    oritavancin diphosphate  
    oritavancin  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$383.3333
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

chlorobiphenyl-chloroeremomycin | ly333328 | ly 333328 | ly-333328 | orbactiv | oritavancin | oritavancin diphosphate

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (2)


 

Infections

Skin Diseases, Infectious (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Abscess (Phase 3)

Arthritis, Infectious (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections (Phase 4)

Cellulitis (Phase 3)

Gram-Positive Bacterial Infections (Phase 1)

Healthy Volunteers (Phase 1)

Infections ()

Inflammation (Phase 3)

Osteomyelitis (Phase 4)

Skin Diseases, Bacterial (Phase 4)

Soft Tissue Infections (Phase 4)

Staphylococcal Infections (Phase 4)

Staphylococcal Skin Infections (Phase 2)

Streptococcal Infections (Phase 2)

Substance-Related Disorders (Phase 4)

Wound Infection (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue